RxDoctor Payments Data

Chloe Douglass, OD

Optometrist · Bangor, MENPI 1669055588

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 39.6% of the total. 2025 is the largest year on record at $478, 4.2 times the $115 reported in 2021.

$1,187in general payments, 2019–2025

Across 43 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$470
  • Bausch & Lomb Americas Inc.$202
  • Biotissue Holdings Inc.$135
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$92
  • Amgen$85
  • Tarsus Pharmaceuticals, Inc.$67
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,187 in reported general payments places this provider in the 85th percentile of 224 optometrist providers in Maine.

See all optometrist providers in Maine

Medicare billing

Part B allowed, 2024
$89,987
Medicare patients
474
Services billed
3,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost46$30,170
RestasisCyclosporine17$26,802
Alphagan PBrimonidine Tartrate22$11,485
Travoprost18$3,328
Brimonidine Tartrate33$2,009
Latanoprost134$2,001
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$1,113
Dorzolamide Hcl44$822
Prednisolone Acetate12$596
ValacyclovirValacyclovir Hcl12$430
Timolol Maleate30$398
MoxifloxacinMoxifloxacin Hcl22$396
Azelastine Hcl18$360
Doxycycline Hyclate17$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$470$68,45785 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 224 optometrist providers in Maine.

Other optometrist in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →